| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| AMGN - Amgen Inc | BUY | 1,434 @ USD 344.57 | USD 494,113 | The ETF bought 1434 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 344.57 compared to the previous average buy price of 291.231. This is 18.3% higher than average price of previous purchases of AMGN. |
| GILD - Guild Esports Plc | BUY | 3,654 @ USD 127.51 | USD 465,922 | The ETF bought 3654 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 127.51 compared to the previous average buy price of 113.872. This is 12.0% higher than average price of previous purchases of GILD. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 1,056 @ USD 432.17 | USD 456,372 | The ETF bought 1056 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 432.17 compared to the previous average buy price of 416.378. This is 3.8% higher than average price of previous purchases of VRTX. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 516 @ USD 784.61 | USD 404,859 | The ETF bought 516 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 784.61 compared to the previous average buy price of 632.682. This is 24.0% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 648 @ USD 445.12 | USD 288,438 | The ETF bought 648 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 445.12 compared to the previous average buy price of 380.543. This is 17.0% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 2,583 @ USD 93.32 | USD 241,046 | The ETF bought 2583 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 93.32 compared to the previous average buy price of 75.9208. This is 22.9% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 1,053 @ USD 204.51 | USD 215,349 | The ETF bought 1053 new shares of INSM (Insmed Inc). The shares were bought for an average price of 204.51 compared to the previous average buy price of 126.095. This is 62.2% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 153 @ USD 917.63 | USD 140,397 | The ETF bought 153 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 917.63 compared to the previous average buy price of 662.076. This is 38.6% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 732 @ USD 181.94 | USD 133,180 | The ETF bought 732 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 181.94 compared to the previous average buy price of 140.872. This is 29.2% higher than average price of previous purchases of BIIB. |
| UTHR - United Therapeutics Corporation | BUY | 225 @ USD 488.43 | USD 109,897 | The ETF bought 225 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 488.43 compared to the previous average buy price of 353.315. This is 38.2% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 975 @ USD 105.65 | USD 103,009 | The ETF bought 975 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 105.65 compared to the previous average buy price of 76.5845. This is 38.0% higher than average price of previous purchases of INCY. |
| ILMN - Illumina Inc | BUY | 765 @ USD 129.81 | USD 99,305 | The ETF bought 765 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 129.81 compared to the previous average buy price of 99.469. This is 30.5% higher than average price of previous purchases of ILMN. |
| RPRX - Royalty Pharma Plc | BUY | 2,151 @ USD 39.84 | USD 85,696 | The ETF bought 2151 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 39.84 compared to the previous average buy price of 35.9102. This is 10.9% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 141 @ USD 606.6 | USD 85,531 | The ETF bought 141 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 606.6 compared to the previous average buy price of 410.599. This is 47.7% higher than average price of previous purchases of MEDP. |
| NBIX - Neurocrine Biosciences Inc | BUY | 495 @ USD 151.58 | USD 75,032 | The ETF bought 495 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 151.58 compared to the previous average buy price of 130.806. This is 15.9% higher than average price of previous purchases of NBIX. |
| RVMD - Revolution Medicines Inc | BUY | 936 @ USD 77.58 | USD 72,615 | The ETF bought 936 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 77.58 compared to the previous average buy price of 43.6917. This is 77.6% higher than average price of previous purchases of RVMD. |
| ROIV - Roivant Sciences Ltd | BUY | 3,399 @ USD 20.87 | USD 70,937 | The ETF bought 3399 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 20.87 compared to the previous average buy price of 13.5572. This is 53.9% higher than average price of previous purchases of ROIV. |
| BBIO - BridgeBio Pharma Inc | BUY | 957 @ USD 71.72 | USD 68,636 | The ETF bought 957 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 71.72 compared to the previous average buy price of 46.5331. This is 54.1% higher than average price of previous purchases of BBIO. |
| GH - Guardant Health Inc | BUY | 624 @ USD 107.79 | USD 67,261 | The ETF bought 624 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 107.79 compared to the previous average buy price of 58.8774. This is 83.1% higher than average price of previous purchases of GH. |
| SNY - Sanofi ADR | BUY | 1,341 @ USD 50.03 | USD 67,090 | The ETF bought 1341 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 50.03 compared to the previous average buy price of 50.0561. This is -0.1% lower than average price of previous purchases of SNY. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 111 @ USD 601.03 | USD 66,714 | The ETF bought 111 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 601.03 compared to the previous average buy price of 365.328. This is 64.5% higher than average price of previous purchases of MDGL. |
| SMMT - Summit Therapeutics PLC | BUY | 3,711 @ USD 17.82 | USD 66,130 | The ETF bought 3711 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.82 compared to the previous average buy price of 21.1279. This is -15.7% lower than average price of previous purchases of SMMT. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 798 @ USD 82.7 | USD 65,995 | The ETF bought 798 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 82.7 compared to the previous average buy price of 50.4894. This is 63.8% higher than average price of previous purchases of IONS. |
| ASND - Ascendis Pharma AS | BUY | 303 @ USD 210.01 | USD 63,633 | The ETF bought 303 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 210.01 compared to the previous average buy price of 180.607. This is 16.3% higher than average price of previous purchases of ASND. |
| VTRS - Viatris Inc | BUY | 5,835 @ USD 10.64 | USD 62,084 | The ETF bought 5835 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 10.64 compared to the previous average buy price of 9.66867. This is 10.0% higher than average price of previous purchases of VTRS. |
| EXEL - Exelixis Inc | BUY | 1,341 @ USD 44.21 | USD 59,286 | The ETF bought 1341 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 44.21 compared to the previous average buy price of 41.093. This is 7.6% higher than average price of previous purchases of EXEL. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 303 @ USD 176.92 | USD 53,607 | The ETF bought 303 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 176.92 compared to the previous average buy price of 126.497. This is 39.9% higher than average price of previous purchases of JAZZ. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 954 @ USD 55.52 | USD 52,966 | The ETF bought 954 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 55.52 compared to the previous average buy price of 57.981. This is -4.2% lower than average price of previous purchases of BMRN. |
| BNTX - BioNTech SE | BUY | 501 @ USD 102.7 | USD 51,453 | The ETF bought 501 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 102.7 compared to the previous average buy price of 104.961. This is -2.2% lower than average price of previous purchases of BNTX. |
| MRNA - Moderna Inc | BUY | 1,938 @ USD 25.01 | USD 48,469 | The ETF bought 1938 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 25.01 compared to the previous average buy price of 28.8801. This is -13.4% lower than average price of previous purchases of MRNA. |
| RNA - Avidity Biosciences Inc | BUY | 639 @ USD 71.56 | USD 45,727 | The ETF bought 639 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 71.56 compared to the previous average buy price of 39.8862. This is 79.4% higher than average price of previous purchases of RNA. |
| HALO - Halozyme Therapeutics Inc | BUY | 582 @ USD 72.66 | USD 42,288 | The ETF bought 582 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 72.66 compared to the previous average buy price of 60.5811. This is 19.9% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 594 @ USD 68.15 | USD 40,481 | The ETF bought 594 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 68.15 compared to the previous average buy price of 44.6865. This is 52.5% higher than average price of previous purchases of CYTK. |
| AXSM - Axsome Therapeutics Inc | BUY | 249 @ USD 150.98 | USD 37,594 | The ETF bought 249 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 150.98 compared to the previous average buy price of 117.333. This is 28.7% higher than average price of previous purchases of AXSM. |
| MRUS - Merus BV | BUY | 378 @ USD 96.09 | USD 36,322 | The ETF bought 378 new shares of MRUS (Merus BV). The shares were bought for an average price of 96.09 compared to the previous average buy price of 66.4988. This is 44.5% higher than average price of previous purchases of MRUS. |
| NUVL - Nuvalent Inc | BUY | 333 @ USD 109.06 | USD 36,317 | The ETF bought 333 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 109.06 compared to the previous average buy price of 84.0313. This is 29.8% higher than average price of previous purchases of NUVL. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 333 @ USD 107.42 | USD 35,771 | The ETF bought 333 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 107.42 compared to the previous average buy price of 77.8409. This is 38.0% higher than average price of previous purchases of RYTM. |
| PTCT - PTC Therapeutics Inc | BUY | 396 @ USD 86.25 | USD 34,155 | The ETF bought 396 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 86.25 compared to the previous average buy price of 56.69. This is 52.1% higher than average price of previous purchases of PTCT. |
| PCVX - Vaxcyte Inc | BUY | 648 @ USD 49.65 | USD 32,173 | The ETF bought 648 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 49.65 compared to the previous average buy price of 44.835. This is 10.7% higher than average price of previous purchases of PCVX. |
| KRYS - Krystal Biotech Inc | BUY | 144 @ USD 218.7 | USD 31,493 | The ETF bought 144 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 218.7 compared to the previous average buy price of 164.659. This is 32.8% higher than average price of previous purchases of KRYS. |
| PTGX - Protagonist Therapeutics Inc | BUY | 312 @ USD 90.07 | USD 28,102 | The ETF bought 312 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 90.07 compared to the previous average buy price of 58.8935. This is 52.9% higher than average price of previous purchases of PTGX. |
| COGT - Cogent Biosciences Inc | BUY | 690 @ USD 40.39 | USD 27,869 | The ETF bought 690 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 40.39 compared to the previous average buy price of 12.8089. This is 215.3% higher than average price of previous purchases of COGT. |
| ALKS - Alkermes Plc | BUY | 825 @ USD 29.72 | USD 24,519 | The ETF bought 825 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 29.72 compared to the previous average buy price of 30.2956. This is -1.9% lower than average price of previous purchases of ALKS. |
| KYMR - Kymera Therapeutics Inc | BUY | 357 @ USD 67.86 | USD 24,226 | The ETF bought 357 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 67.86 compared to the previous average buy price of 48.0626. This is 41.2% higher than average price of previous purchases of KYMR. |
| CRSP - Crispr Therapeutics AG | BUY | 453 @ USD 53.3 | USD 24,145 | The ETF bought 453 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 53.3 compared to the previous average buy price of 52.6099. This is 1.3% higher than average price of previous purchases of CRSP. |
| ADMA - ADMA Biologics Inc | BUY | 1,200 @ USD 19.14 | USD 22,968 | The ETF bought 1200 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 19.14 compared to the previous average buy price of 17.3646. This is 10.2% higher than average price of previous purchases of ADMA. |
| AKRO - Akero Therapeutics Inc | BUY | 399 @ USD 54.35 | USD 21,686 | The ETF bought 399 new shares of AKRO (Akero Therapeutics Inc). The shares were bought for an average price of 54.35 compared to the previous average buy price of 49.6113. This is 9.6% higher than average price of previous purchases of AKRO. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 471 @ USD 46.03 | USD 21,680 | The ETF bought 471 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 46.03 compared to the previous average buy price of 35.5666. This is 29.4% higher than average price of previous purchases of CRNX. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 849 @ USD 24.81 | USD 21,064 | The ETF bought 849 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 24.81 compared to the previous average buy price of 21.1169. This is 17.5% higher than average price of previous purchases of ACAD. |
| SRRK - Scholar Rock Holding Corp | BUY | 483 @ USD 43.15 | USD 20,841 | The ETF bought 483 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 43.15 compared to the previous average buy price of 35.3804. This is 22.0% higher than average price of previous purchases of SRRK. |
| IMVT - Immunovant Inc | BUY | 879 @ USD 23.7 | USD 20,832 | The ETF bought 879 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 23.7 compared to the previous average buy price of 18.4096. This is 28.7% higher than average price of previous purchases of IMVT. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 99 @ USD 206.16 | USD 20,410 | The ETF bought 99 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 206.16 compared to the previous average buy price of 138.701. This is 48.6% higher than average price of previous purchases of LGND. |
| ACLX - Arcellx Inc | BUY | 276 @ USD 73.25 | USD 20,217 | The ETF bought 276 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 73.25 compared to the previous average buy price of 72.8979. This is 0.5% higher than average price of previous purchases of ACLX. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 1,584 @ USD 12.52 | USD 19,832 | The ETF bought 1584 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.52 compared to the previous average buy price of 9.05874. This is 38.2% higher than average price of previous purchases of AMRX. |
| GRAL - GRAIL, LLC | BUY | 180 @ USD 110.16 | USD 19,829 | The ETF bought 180 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 110.16 compared to the previous average buy price of 55.4397. This is 98.7% higher than average price of previous purchases of GRAL. |
| PRAX - Praxis Precision Medicines Inc | BUY | 105 @ USD 188.54 | USD 19,797 | The ETF bought 105 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 188.54 compared to the previous average buy price of 72.1115. This is 161.5% higher than average price of previous purchases of PRAX. |
| VCYT - Veracyte Inc | BUY | 396 @ USD 47.71 | USD 18,893 | The ETF bought 396 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 47.71 compared to the previous average buy price of 32.124. This is 48.5% higher than average price of previous purchases of VCYT. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 252 @ USD 73.13 | USD 18,429 | The ETF bought 252 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 73.13 compared to the previous average buy price of 56.7346. This is 28.9% higher than average price of previous purchases of MIRM. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 594 @ USD 30.96 | USD 18,390 | The ETF bought 594 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 30.96 compared to the previous average buy price of 17.1968. This is 80.0% higher than average price of previous purchases of ARQT. |
| CGON - CG Oncology, Inc. Common stock | BUY | 384 @ USD 44.84 | USD 17,219 | The ETF bought 384 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 44.84 compared to the previous average buy price of 30.8735. This is 45.2% higher than average price of previous purchases of CGON. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 387 @ USD 44.49 | USD 17,218 | The ETF bought 387 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 44.49 compared to the previous average buy price of 36.0282. This is 23.5% higher than average price of previous purchases of XENE. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 213 @ USD 80.5 | USD 17,147 | The ETF bought 213 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 80.5 compared to the previous average buy price of 51.2039. This is 57.2% higher than average price of previous purchases of TARS. |
| RARE - Ultragenyx | BUY | 486 @ USD 33.76 | USD 16,407 | The ETF bought 486 new shares of RARE (Ultragenyx). The shares were bought for an average price of 33.76 compared to the previous average buy price of 36.0173. This is -6.3% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 486 @ USD 33.76 | USD 16,407 | The ETF bought 486 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 33.76 compared to the previous average buy price of 36.0173. This is -6.3% lower than average price of previous purchases of RARE. |
| IRON - Ironveld Plc | BUY | 174 @ USD 93.75 | USD 16,313 | The ETF bought 174 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 93.75 compared to the previous average buy price of 61.0451. This is 53.6% higher than average price of previous purchases of IRON. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 228 @ USD 70.39 | USD 16,049 | The ETF bought 228 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 70.39 compared to the previous average buy price of 45.5928. This is 54.4% higher than average price of previous purchases of APGE. |
| TVTX - Travere Therapeutics Inc | BUY | 441 @ USD 36.26 | USD 15,991 | The ETF bought 441 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 36.26 compared to the previous average buy price of 21.0157. This is 72.5% higher than average price of previous purchases of TVTX. |
| IDYA - Ideaya Biosciences Inc | BUY | 444 @ USD 35.88 | USD 15,931 | The ETF bought 444 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 35.88 compared to the previous average buy price of 24.2041. This is 48.2% higher than average price of previous purchases of IDYA. |
| FOLD - Amicus Therapeutics Inc | BUY | 1,530 @ USD 10.02 | USD 15,331 | The ETF bought 1530 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 10.02 compared to the previous average buy price of 7.53747. This is 32.9% higher than average price of previous purchases of FOLD. |
| DYN - Dyne Therapeutics Inc | BUY | 717 @ USD 21.17 | USD 15,179 | The ETF bought 717 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 21.17 compared to the previous average buy price of 13.3439. This is 58.6% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 717 @ USD 21.17 | USD 15,179 | The ETF bought 717 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 21.17 compared to the previous average buy price of 13.3439. This is 58.6% higher than average price of previous purchases of DYN. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 756 @ USD 19.72 | USD 14,908 | The ETF bought 756 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 19.72 compared to the previous average buy price of 12.2354. This is 61.2% higher than average price of previous purchases of ADPT. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 327 @ USD 43.36 | USD 14,179 | The ETF bought 327 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 43.36 compared to the previous average buy price of 21.1678. This is 104.8% higher than average price of previous purchases of MLYS. |
| DNLI - Denali Therapeutics Inc | BUY | 726 @ USD 19.4 | USD 14,084 | The ETF bought 726 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 19.4 compared to the previous average buy price of 15.3706. This is 26.2% higher than average price of previous purchases of DNLI. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 474 @ USD 28.98 | USD 13,737 | The ETF bought 474 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 28.98 compared to the previous average buy price of 17.2951. This is 67.6% higher than average price of previous purchases of CNTA. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 636 @ USD 21.59 | USD 13,731 | The ETF bought 636 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 21.59 compared to the previous average buy price of 20.9295. This is 3.2% higher than average price of previous purchases of APLS. |
| EWTX - Edgewise Therapeutics Inc | BUY | 522 @ USD 25.52 | USD 13,321 | The ETF bought 522 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 25.52 compared to the previous average buy price of 16.3772. This is 55.8% higher than average price of previous purchases of EWTX. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 282 @ USD 46.26 | USD 13,045 | The ETF bought 282 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 46.26 compared to the previous average buy price of 38.0457. This is 21.6% higher than average price of previous purchases of SUPN. |
| BEAM - Beam Therapeutics Inc | BUY | 501 @ USD 25.03 | USD 12,540 | The ETF bought 501 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 25.03 compared to the previous average buy price of 20.7535. This is 20.6% higher than average price of previous purchases of BEAM. |
| TERN - Tern Plc | BUY | 435 @ USD 28.75 | USD 12,506 | The ETF bought 435 new shares of TERN (Tern Plc). The shares were bought for an average price of 28.75 compared to the previous average buy price of 6.96231. This is 312.9% higher than average price of previous purchases of TERN. |
| LEGN - Legend Biotech Corp | BUY | 420 @ USD 27.5 | USD 11,550 | The ETF bought 420 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 27.5 compared to the previous average buy price of 34.261. This is -19.7% lower than average price of previous purchases of LEGN. |
| TXG - 10X Genomics Inc | BUY | 573 @ USD 18.75 | USD 10,744 | The ETF bought 573 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 18.75 compared to the previous average buy price of 12.5441. This is 49.5% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 573 @ USD 18.75 | USD 10,744 | The ETF bought 573 new shares of TXG (Terex Corporation). The shares were bought for an average price of 18.75 compared to the previous average buy price of 12.5441. This is 49.5% higher than average price of previous purchases of TXG. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 654 @ USD 16.37 | USD 10,706 | The ETF bought 654 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 16.37 compared to the previous average buy price of 9.72328. This is 68.4% higher than average price of previous purchases of AUPH. |
| VERA - Vera Therapeutics Inc | BUY | 318 @ USD 33.33 | USD 10,599 | The ETF bought 318 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 33.33 compared to the previous average buy price of 26.9713. This is 23.6% higher than average price of previous purchases of VERA. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 384 @ USD 27.33 | USD 10,495 | The ETF bought 384 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 27.33 compared to the previous average buy price of 15.1753. This is 80.1% higher than average price of previous purchases of ZYME. |
| OCUL - Ocular Therapeutix Inc | BUY | 864 @ USD 12.14 | USD 10,489 | The ETF bought 864 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 12.14 compared to the previous average buy price of 10.1357. This is 19.8% higher than average price of previous purchases of OCUL. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 483 @ USD 21.4 | USD 10,336 | The ETF bought 483 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 21.4 compared to the previous average buy price of 11.9091. This is 79.7% higher than average price of previous purchases of AVDL. |
| JANX - Janux Therapeutics Inc | BUY | 297 @ USD 34.69 | USD 10,303 | The ETF bought 297 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 34.69 compared to the previous average buy price of 27.9187. This is 24.3% higher than average price of previous purchases of JANX. |
| SRPT - Sarepta Therapeutics Inc | BUY | 486 @ USD 20.95 | USD 10,182 | The ETF bought 486 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 20.95 compared to the previous average buy price of 32.6995. This is -35.9% lower than average price of previous purchases of SRPT. |
| IBRX - Immunitybio Inc | BUY | 4,773 @ USD 2.13 | USD 10,166 | The ETF bought 4773 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.13 compared to the previous average buy price of 2.71336. This is -21.5% lower than average price of previous purchases of IBRX. |
| HRMY - Harmony Biosciences Holdings | BUY | 285 @ USD 35.56 | USD 10,135 | The ETF bought 285 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 35.56 compared to the previous average buy price of 32.075. This is 10.9% higher than average price of previous purchases of HRMY. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 294 @ USD 34.22 | USD 10,061 | The ETF bought 294 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 34.22 compared to the previous average buy price of 24.0316. This is 42.4% higher than average price of previous purchases of GPCR. |
| VCEL - Vericel Corp Ord | BUY | 249 @ USD 40.37 | USD 10,052 | The ETF bought 249 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 40.37 compared to the previous average buy price of 40.7189. This is -0.9% lower than average price of previous purchases of VCEL. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 2,166 @ USD 4.41 | USD 9,552 | The ETF bought 2166 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.41 compared to the previous average buy price of 5.68333. This is -22.4% lower than average price of previous purchases of RXRX. |
| TWST - Twist Bioscience Corp | BUY | 300 @ USD 31.7 | USD 9,510 | The ETF bought 300 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 31.7 compared to the previous average buy price of 35.645. This is -11.1% lower than average price of previous purchases of TWST. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 336 @ USD 28.12 | USD 9,448 | The ETF bought 336 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 28.12 compared to the previous average buy price of 6.56097. This is 328.6% higher than average price of previous purchases of OLMA. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 219 @ USD 42.54 | USD 9,316 | The ETF bought 219 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 42.54 compared to the previous average buy price of 30.7706. This is 38.2% higher than average price of previous purchases of KNSA. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 108 @ USD 84.36 | USD 9,111 | The ETF bought 108 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 84.36 compared to the previous average buy price of 72.5285. This is 16.3% higher than average price of previous purchases of ANIP. |
| SYRE - Spyre Therapeutics Inc. | BUY | 297 @ USD 29.75 | USD 8,836 | The ETF bought 297 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 29.75 compared to the previous average buy price of 18.1824. This is 63.6% higher than average price of previous purchases of SYRE. |
| STOK - Stoke Therapeutics Inc | BUY | 279 @ USD 31.21 | USD 8,708 | The ETF bought 279 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 31.21 compared to the previous average buy price of 16.8392. This is 85.3% higher than average price of previous purchases of STOK. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 429 @ USD 19.87 | USD 8,524 | The ETF bought 429 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 19.87 compared to the previous average buy price of 12.1698. This is 63.3% higher than average price of previous purchases of SNDX. |
| AGIO - Agios Pharm | BUY | 288 @ USD 29.04 | USD 8,364 | The ETF bought 288 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 29.04 compared to the previous average buy price of 36.1077. This is -19.6% lower than average price of previous purchases of AGIO. |
| MNKD - MannKind Corp | BUY | 1,530 @ USD 5.38 | USD 8,231 | The ETF bought 1530 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.38 compared to the previous average buy price of 4.74867. This is 13.3% higher than average price of previous purchases of MNKD. |
| IMCR - Immunocore Holdings Ltd | BUY | 204 @ USD 40.13 | USD 8,187 | The ETF bought 204 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 40.13 compared to the previous average buy price of 33.2374. This is 20.7% higher than average price of previous purchases of IMCR. |
| QURE - Uniqure NV | BUY | 276 @ USD 27.63 | USD 7,626 | The ETF bought 276 new shares of QURE (Uniqure NV). The shares were bought for an average price of 27.63 compared to the previous average buy price of 23.36. This is 18.3% higher than average price of previous purchases of QURE. |
| HROW - Harrow Health Inc | BUY | 183 @ USD 41.3 | USD 7,558 | The ETF bought 183 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 41.3 compared to the previous average buy price of 33.904. This is 21.8% higher than average price of previous purchases of HROW. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 1,047 @ USD 7.1 | USD 7,434 | The ETF bought 1047 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.1 compared to the previous average buy price of 8.19533. This is -13.4% lower than average price of previous purchases of BCRX. |
| COLL - Collegium Pharmaceutical Inc | BUY | 156 @ USD 46.23 | USD 7,212 | The ETF bought 156 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 46.23 compared to the previous average buy price of 32.801. This is 40.9% higher than average price of previous purchases of COLL. |
| ARDX - Ardelyx Inc | BUY | 1,206 @ USD 5.93 | USD 7,152 | The ETF bought 1206 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 5.93 compared to the previous average buy price of 4.71615. This is 25.7% higher than average price of previous purchases of ARDX. |
| NVCR - Novocure Ltd | BUY | 558 @ USD 12.76 | USD 7,120 | The ETF bought 558 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 12.76 compared to the previous average buy price of 16.291. This is -21.7% lower than average price of previous purchases of NVCR. |
| URGN - UroGen Pharma Ltd | BUY | 237 @ USD 29.42 | USD 6,973 | The ETF bought 237 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 29.42 compared to the previous average buy price of 15.4861. This is 90.0% higher than average price of previous purchases of URGN. |
| NRIX - Nurix Therapeutics Inc | BUY | 402 @ USD 17.2 | USD 6,914 | The ETF bought 402 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 17.2 compared to the previous average buy price of 12.2582. This is 40.3% higher than average price of previous purchases of NRIX. |
| RLAY - Relay Therapeutics Inc | BUY | 861 @ USD 8.03 | USD 6,914 | The ETF bought 861 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 8.03 compared to the previous average buy price of 4.3465. This is 84.7% higher than average price of previous purchases of RLAY. |
| INVA - Innoviva Inc | BUY | 312 @ USD 21.71 | USD 6,774 | The ETF bought 312 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 21.71 compared to the previous average buy price of 19.1501. This is 13.4% higher than average price of previous purchases of INVA. |
| DVAX - Dynavax Technologies Corporation | BUY | 585 @ USD 11.43 | USD 6,687 | The ETF bought 585 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 11.43 compared to the previous average buy price of 10.5634. This is 8.2% higher than average price of previous purchases of DVAX. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 444 @ USD 15 | USD 6,660 | The ETF bought 444 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 15 compared to the previous average buy price of 7.38166. This is 103.2% higher than average price of previous purchases of AMLX. |
| TSHA - Taysha Gene Therapies Inc | BUY | 1,365 @ USD 4.86 | USD 6,634 | The ETF bought 1365 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.86 compared to the previous average buy price of 2.97117. This is 63.6% higher than average price of previous purchases of TSHA. |
| GMAB - Genmab AS | BUY | 207 @ USD 31.92 | USD 6,607 | The ETF bought 207 new shares of GMAB (Genmab AS). The shares were bought for an average price of 31.92 compared to the previous average buy price of 23.997. This is 33.0% higher than average price of previous purchases of GMAB. |
| ELVN - Enliven Therapeutics Inc. | BUY | 294 @ USD 21.71 | USD 6,383 | The ETF bought 294 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 21.71 compared to the previous average buy price of 20.5007. This is 5.9% higher than average price of previous purchases of ELVN. |
| AMPH - Amphastar P | BUY | 231 @ USD 27.36 | USD 6,320 | The ETF bought 231 new shares of AMPH (Amphastar P). The shares were bought for an average price of 27.36 compared to the previous average buy price of 25.5539. This is 7.1% higher than average price of previous purchases of AMPH. |
| WVE - Wave Life Sciences Ltd | BUY | 816 @ USD 7.67 | USD 6,259 | The ETF bought 816 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 7.67 compared to the previous average buy price of 8.34465. This is -8.1% lower than average price of previous purchases of WVE. |
| XNCR - Xencor Inc | BUY | 357 @ USD 17.38 | USD 6,205 | The ETF bought 357 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 17.38 compared to the previous average buy price of 11.5122. This is 51.0% higher than average price of previous purchases of XNCR. |
| CVAC - CureVac NV | BUY | 1,128 @ USD 5.48 | USD 6,181 | The ETF bought 1128 new shares of CVAC (CureVac NV). The shares were bought for an average price of 5.48 compared to the previous average buy price of 4.87618. This is 12.4% higher than average price of previous purchases of CVAC. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 834 @ USD 7.18 | USD 5,988 | The ETF bought 834 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.18 compared to the previous average buy price of 6.12686. This is 17.2% higher than average price of previous purchases of XERS. |
| TNGX - Tango Therapeutics Inc | BUY | 555 @ USD 10.76 | USD 5,972 | The ETF bought 555 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 10.76 compared to the previous average buy price of 6.4654. This is 66.4% higher than average price of previous purchases of TNGX. |
| ANAB - AnaptysBio Inc | BUY | 138 @ USD 42.16 | USD 5,818 | The ETF bought 138 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 42.16 compared to the previous average buy price of 25.2534. This is 66.9% higher than average price of previous purchases of ANAB. |
| CSTL - Castle Biosciences Inc | BUY | 144 @ USD 39.94 | USD 5,751 | The ETF bought 144 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 39.94 compared to the previous average buy price of 22.8909. This is 74.5% higher than average price of previous purchases of CSTL. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 486 @ USD 11.82 | USD 5,745 | The ETF bought 486 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 11.82 compared to the previous average buy price of 10.5818. This is 11.7% higher than average price of previous purchases of ORIC. |
| FTRE - Fortrea Holdings Inc. | BUY | 453 @ USD 12.63 | USD 5,721 | The ETF bought 453 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 12.63 compared to the previous average buy price of 7.01335. This is 80.1% higher than average price of previous purchases of FTRE. |
| PGEN - Precigen Inc | BUY | 1,527 @ USD 3.74 | USD 5,711 | The ETF bought 1527 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 3.74 compared to the previous average buy price of 2.45657. This is 52.2% higher than average price of previous purchases of PGEN. |
| NVAX - Novavax Inc | BUY | 813 @ USD 6.95 | USD 5,650 | The ETF bought 813 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 6.95 compared to the previous average buy price of 7.31355. This is -5.0% lower than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 813 @ USD 6.95 | USD 5,650 | The ETF bought 813 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 6.95 compared to the previous average buy price of 7.31355. This is -5.0% lower than average price of previous purchases of NVAX. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 363 @ USD 15.17 | USD 5,507 | The ETF bought 363 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 15.17 compared to the previous average buy price of 9.48058. This is 60.0% higher than average price of previous purchases of PHAT. |
| ABCL - Abcellera Biologics Inc | BUY | 1,500 @ USD 3.64 | USD 5,460 | The ETF bought 1500 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.64 compared to the previous average buy price of 3.90068. This is -6.7% lower than average price of previous purchases of ABCL. |
| KURA - Kura Oncology Inc | BUY | 453 @ USD 11.99 | USD 5,431 | The ETF bought 453 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 11.99 compared to the previous average buy price of 7.54994. This is 58.8% higher than average price of previous purchases of KURA. |
| GRFS - Grifols SA ADR | BUY | 612 @ USD 8.78 | USD 5,373 | The ETF bought 612 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 8.78 compared to the previous average buy price of 9.34968. This is -6.1% lower than average price of previous purchases of GRFS. |
| PCRX - Pacira BioSciences, Inc. | BUY | 225 @ USD 23.81 | USD 5,357 | The ETF bought 225 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 23.81 compared to the previous average buy price of 23.7795. This is 0.1% higher than average price of previous purchases of PCRX. |
| SANA - Sana Biotechnology Inc | BUY | 1,320 @ USD 4.02 | USD 5,306 | The ETF bought 1320 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.02 compared to the previous average buy price of 3.24633. This is 23.8% higher than average price of previous purchases of SANA. |
| EYPT - Eyepoint Pharmaceuticals Inc | BUY | 345 @ USD 14.79 | USD 5,103 | The ETF bought 345 new shares of EYPT (Eyepoint Pharmaceuticals Inc). The shares were bought for an average price of 14.79 compared to the previous average buy price of 9.11658. This is 62.2% higher than average price of previous purchases of EYPT. |
| TBPH - Theravance Biopharma Inc | BUY | 252 @ USD 19.96 | USD 5,030 | The ETF bought 252 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 19.96 compared to the previous average buy price of 12.307. This is 62.2% higher than average price of previous purchases of TBPH. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 510 @ USD 9.41 | USD 4,799 | The ETF bought 510 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 9.41 compared to the previous average buy price of 7.54496. This is 24.7% higher than average price of previous purchases of DAWN. |
| ZLAB - Zai Lab Ltd | BUY | 240 @ USD 19.97 | USD 4,793 | The ETF bought 240 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 19.97 compared to the previous average buy price of 33.1743. This is -39.8% lower than average price of previous purchases of ZLAB. |
| ERAS - Erasca Inc | BUY | 1,527 @ USD 3.13 | USD 4,780 | The ETF bought 1527 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 3.13 compared to the previous average buy price of 1.76005. This is 77.8% higher than average price of previous purchases of ERAS. |
| MNMD - Mind Medicine Inc | BUY | 390 @ USD 12.1 | USD 4,719 | The ETF bought 390 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 12.1 compared to the previous average buy price of 8.839. This is 36.9% higher than average price of previous purchases of MNMD. |
| SPRY - Silverback Therapeutics Inc | BUY | 492 @ USD 9.57 | USD 4,708 | The ETF bought 492 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 9.57 compared to the previous average buy price of 13.2725. This is -27.9% lower than average price of previous purchases of SPRY. |
| NTLA - Intellia Therapeutics Inc | BUY | 546 @ USD 8.52001 | USD 4,652 | The ETF bought 546 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 8.52001 compared to the previous average buy price of 12.1201. This is -29.7% lower than average price of previous purchases of NTLA. |
| SVRA - Savara Inc | BUY | 867 @ USD 5.36 | USD 4,647 | The ETF bought 867 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.36 compared to the previous average buy price of 2.98735. This is 79.4% higher than average price of previous purchases of SVRA. |
| ARVN - Arvinas Inc | BUY | 360 @ USD 12.42 | USD 4,471 | The ETF bought 360 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.42 compared to the previous average buy price of 9.00076. This is 38.0% higher than average price of previous purchases of ARVN. |
| VIR - Vir Biotechnology Inc | BUY | 693 @ USD 6.39 | USD 4,428 | The ETF bought 693 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 6.39 compared to the previous average buy price of 5.83349. This is 9.5% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 693 @ USD 6.39 | USD 4,428 | The ETF bought 693 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 6.39 compared to the previous average buy price of 5.83349. This is 9.5% higher than average price of previous purchases of VIR. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,785 @ USD 2.44 | USD 4,355 | The ETF bought 1785 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.44 compared to the previous average buy price of 2.43788. This is 0.1% higher than average price of previous purchases of IOVA. |
| ABUS - Arbutus Biopharma Corp | BUY | 984 @ USD 4.41 | USD 4,339 | The ETF bought 984 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.41 compared to the previous average buy price of 3.70071. This is 19.2% higher than average price of previous purchases of ABUS. |
| PAHC - Phibro Animal Health Corporation | BUY | 99 @ USD 43.23 | USD 4,280 | The ETF bought 99 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 43.23 compared to the previous average buy price of 29.6334. This is 45.9% higher than average price of previous purchases of PAHC. |
| REPL - Replimune Group Inc | BUY | 402 @ USD 10.06 | USD 4,044 | The ETF bought 402 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 10.06 compared to the previous average buy price of 8.88172. This is 13.3% higher than average price of previous purchases of REPL. |
| PACB - Pacific Biosciences of California | BUY | 1,596 @ USD 2.39 | USD 3,814 | The ETF bought 1596 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.39 compared to the previous average buy price of 1.57274. This is 52.0% higher than average price of previous purchases of PACB. |
| GERN - Geron Corporation | BUY | 3,195 @ USD 1.19 | USD 3,802 | The ETF bought 3195 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.19 compared to the previous average buy price of 1.47885. This is -19.5% lower than average price of previous purchases of GERN. |
| CGEM - Cullinan Oncology LLC | BUY | 309 @ USD 11.74 | USD 3,628 | The ETF bought 309 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 11.74 compared to the previous average buy price of 8.04511. This is 45.9% higher than average price of previous purchases of CGEM. |
| KROS - Keros Therapeutics Inc | BUY | 201 @ USD 17.5 | USD 3,518 | The ETF bought 201 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 17.5 compared to the previous average buy price of 14.0423. This is 24.6% higher than average price of previous purchases of KROS. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 249 @ USD 14.1 | USD 3,511 | The ETF bought 249 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 14.1 compared to the previous average buy price of 12.4799. This is 13.0% higher than average price of previous purchases of KALV. |
| RGNX - Regenxbio Inc | BUY | 264 @ USD 13.26 | USD 3,501 | The ETF bought 264 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 13.26 compared to the previous average buy price of 9.38782. This is 41.2% higher than average price of previous purchases of RGNX. |
| MGTX - MeiraGTx Holdings PLC | BUY | 408 @ USD 8.19999 | USD 3,346 | The ETF bought 408 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.19999 compared to the previous average buy price of 7.25677. This is 13.0% higher than average price of previous purchases of MGTX. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 885 @ USD 3.71 | USD 3,283 | The ETF bought 885 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.71 compared to the previous average buy price of 4.48396. This is -17.3% lower than average price of previous purchases of PRME. |
| PRTA - Prothena Corporation plc | BUY | 279 @ USD 10.43 | USD 2,910 | The ETF bought 279 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.43 compared to the previous average buy price of 9.11333. This is 14.4% higher than average price of previous purchases of PRTA. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 795 @ USD 3.64 | USD 2,894 | The ETF bought 795 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.64 compared to the previous average buy price of 2.78022. This is 30.9% higher than average price of previous purchases of MRVI. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 255 @ USD 10.99 | USD 2,802 | The ETF bought 255 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 10.99 compared to the previous average buy price of 6.75396. This is 62.7% higher than average price of previous purchases of FDMT. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 1,926 @ USD 1.43 | USD 2,754 | The ETF bought 1926 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.43 compared to the previous average buy price of 1.08961. This is 31.2% higher than average price of previous purchases of LXRX. |
| EOLS - Evolus Inc | BUY | 357 @ USD 7.03999 | USD 2,513 | The ETF bought 357 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 7.03999 compared to the previous average buy price of 9.01105. This is -21.9% lower than average price of previous purchases of EOLS. |
| LYEL - Lyell Immunopharma Inc | BUY | 96 @ USD 24.41 | USD 2,343 | The ETF bought 96 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 24.41 compared to the previous average buy price of 6.86621. This is 255.5% higher than average price of previous purchases of LYEL. |
| GLPG - Galapagos NV ADR | BUY | 75 @ USD 31.13 | USD 2,335 | The ETF bought 75 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 31.13 compared to the previous average buy price of 29.2976. This is 6.3% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 75 @ USD 31.13 | USD 2,335 | The ETF bought 75 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 31.13 compared to the previous average buy price of 29.2976. This is 6.3% higher than average price of previous purchases of GLPG. |
| HCM - HUTCHMED China Ltd | BUY | 162 @ USD 14.32 | USD 2,320 | The ETF bought 162 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 14.32 compared to the previous average buy price of 15.4133. This is -7.1% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 162 @ USD 14.32 | USD 2,320 | The ETF bought 162 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 14.32 compared to the previous average buy price of 15.4133. This is -7.1% lower than average price of previous purchases of HCM. |
| ALT - Altitude Group Plc | BUY | 435 @ USD 5.17001 | USD 2,249 | The ETF bought 435 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 5.17001 compared to the previous average buy price of 5.1524. This is 0.3% higher than average price of previous purchases of ALT. |
| SIGA - SIGA Technologies Inc | BUY | 360 @ USD 6.04 | USD 2,174 | The ETF bought 360 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.04 compared to the previous average buy price of 6.74234. This is -10.4% lower than average price of previous purchases of SIGA. |
| TRDA - Entrada Therapeutics Inc | BUY | 210 @ USD 10.08 | USD 2,117 | The ETF bought 210 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 10.08 compared to the previous average buy price of 7.77118. This is 29.7% higher than average price of previous purchases of TRDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 552 @ USD 3.28999 | USD 1,816 | The ETF bought 552 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.28999 compared to the previous average buy price of 4.95366. This is -33.6% lower than average price of previous purchases of RCKT. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 243 @ USD 7.31 | USD 1,776 | The ETF bought 243 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 7.31 compared to the previous average buy price of 8.40124. This is -13.0% lower than average price of previous purchases of BCYC. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 333 @ USD 5.30001 | USD 1,765 | The ETF bought 333 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 5.30001 compared to the previous average buy price of 4.86307. This is 9.0% higher than average price of previous purchases of VNDA. |
| AVXL - Anavex Life Sciences Corp | BUY | 447 @ USD 3.86001 | USD 1,725 | The ETF bought 447 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 3.86001 compared to the previous average buy price of 9.03041. This is -57.3% lower than average price of previous purchases of AVXL. |
| ALLO - Allogene Therapeutics Inc | BUY | 1,140 @ USD 1.42 | USD 1,619 | The ETF bought 1140 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.42 compared to the previous average buy price of 1.33093. This is 6.7% higher than average price of previous purchases of ALLO. |
| AUTL - Autolus Therapeutics Ltd | BUY | 1,128 @ USD 1.37 | USD 1,545 | The ETF bought 1128 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.37 compared to the previous average buy price of 1.80726. This is -24.2% lower than average price of previous purchases of AUTL. |
| ACIU - AC Immune Ltd | BUY | 519 @ USD 2.93 | USD 1,521 | The ETF bought 519 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 2.93 compared to the previous average buy price of 2.46595. This is 18.8% higher than average price of previous purchases of ACIU. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 432 @ USD 3.05 | USD 1,318 | The ETF bought 432 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.05 compared to the previous average buy price of 3.30966. This is -7.8% lower than average price of previous purchases of AVIR. |
| OABI - OmniAb Inc. | BUY | 642 @ USD 1.86 | USD 1,194 | The ETF bought 642 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.86 compared to the previous average buy price of 1.89089. This is -1.6% lower than average price of previous purchases of OABI. |
| EDIT - Editas Medicine Inc | BUY | 495 @ USD 2.4 | USD 1,188 | The ETF bought 495 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.4 compared to the previous average buy price of 2.71613. This is -11.6% lower than average price of previous purchases of EDIT. |
| HUMA - Humacyte Inc | BUY | 846 @ USD 1.33 | USD 1,125 | The ETF bought 846 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.33 compared to the previous average buy price of 2.14171. This is -37.9% lower than average price of previous purchases of HUMA. |
| VYGR - Voyager Therapeutics Inc | BUY | 267 @ USD 4.02999 | USD 1,076 | The ETF bought 267 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.02999 compared to the previous average buy price of 3.87524. This is 4.0% higher than average price of previous purchases of VYGR. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 147 @ USD 6.80001 | USD 1,000 | The ETF bought 147 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 6.80001 compared to the previous average buy price of 13.8993. This is -51.1% lower than average price of previous purchases of ARCT. |
| MXCT - MaxCyte Inc | BUY | 555 @ USD 1.75 | USD 971 | The ETF bought 555 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.75 compared to the previous average buy price of 2.12638. This is -17.7% lower than average price of previous purchases of MXCT. |
| ALEC - Alector Inc | BUY | 549 @ USD 1.35 | USD 741 | The ETF bought 549 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.35 compared to the previous average buy price of 1.85538. This is -27.2% lower than average price of previous purchases of ALEC. |
| MRSN - Mersana Therapeutics Inc | BUY | 24 @ USD 27.5399 | USD 661 | The ETF bought 24 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 27.5399 compared to the previous average buy price of 0.754702. This is 3,549.1% higher than average price of previous purchases of MRSN. |
| FATE - Fate Therapeutics Inc | BUY | 567 @ USD 1.09999 | USD 624 | The ETF bought 567 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.09999 compared to the previous average buy price of 1.17046. This is -6.0% lower than average price of previous purchases of FATE. |
| MGNX - MacroGenics Inc | BUY | 321 @ USD 1.48 | USD 475 | The ETF bought 321 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.48 compared to the previous average buy price of 1.56725. This is -5.6% lower than average price of previous purchases of MGNX. |
| PLRX - Pliant Therapeutics Inc | BUY | 300 @ USD 1.57999 | USD 474 | The ETF bought 300 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.57999 compared to the previous average buy price of 1.50472. This is 5.0% higher than average price of previous purchases of PLRX. |
| BMEA - Biomea Fusion Inc | BUY | 357 @ USD 1.07 | USD 382 | The ETF bought 357 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.07 compared to the previous average buy price of 1.69148. This is -36.7% lower than average price of previous purchases of BMEA. |
| STRO - Sutro Biopharma | BUY | 408 @ USD 0.886293 | USD 362 | The ETF bought 408 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 0.886293 compared to the previous average buy price of 0.897301. This is -1.2% lower than average price of previous purchases of STRO. |
| OKUR - OKUR | BUY | 63 @ USD 2.86 | USD 180 | The ETF bought 63 new shares of OKUR (OKUR). The shares were bought for an average price of 2.86 compared to the previous average buy price of 5.94412. This is -51.9% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 57.71 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 57.71. The average price that ARWR shares were previous bought at was USD 22.7392. The current market price is 153.8% higher than average price they were purchased at. The value of the holding in ARWR has increased by USD 1,011,880 compared to the previous valuation of Arrowhead Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 3.86 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 3.86. The average price that IRWD shares were previous bought at was USD 1.37291. The current market price is 181.2% higher than average price they were purchased at. The value of the holding in IRWD has increased by USD 74,134 compared to the previous valuation of Ironwood Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |